Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

(2010) Nancy Diazgranados et al.   ARCHIVES OF GENERAL PSYCHIATRY

Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions

(2010) Kenji Hashimoto   PSYCHIATRY AND CLINICAL NEUROSCIENCES

A Glutamate Pathway to Faster-Acting Antidepressants?

(2010) J. F. Cryan et al.   SCIENCE

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

(2010) N. Li et al.   SCIENCE

Glutamatergic Modulators: The Future of Treating Mood Disorders?

(2010) Carlos Zarate et al.   HARVARD REVIEW OF PSYCHIATRY

Emerging role of glutamate in the pathophysiology of major depressive disorder

(2009) Kenji Hashimoto   BRAIN RESEARCH REVIEWS

The Sigma Enigma: Can Sigma Receptors Provide a Novel Target for Disorders of Mood and Cognition?

(2009) Stephen M. Stahl   JOURNAL OF CLINICAL PSYCHIATRY

Comments on "An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-d-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder"

(2009) Kenji Hashimoto   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Translational Control of Long-Lasting Synaptic Plasticity and Memory

(2009) Mauro Costa-Mattioli et al.   NEURON

BDNF Activates mTOR to Regulate GluR1 Expression Required for Memory Formation

(2009) Leandro Slipczuk et al.   PLoS One

mTOR signaling: At the crossroads of plasticity, memory and disease

(2009) Charles A. Hoeffer et al.   TRENDS IN NEUROSCIENCES

Glutamate-based antidepressants: 20 years on

(2009) Phil Skolnick et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications

(2008) Srijan Sen et al.   BIOLOGICAL PSYCHIATRY

Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders

(2008) C. Cleary et al.   BRAIN RESEARCH BULLETIN

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

(2008) Sheldon H. Preskorn et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

(2008) Gerard Sanacora et al.   NATURE REVIEWS DRUG DISCOVERY

Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors

(2007) Sungho Maeng et al.   BIOLOGICAL PSYCHIATRY